The pharmaceutical industry argues that because new drugs will not be developed unless heavy development costs can be recouped in later sales, the current 20 years of protection provided by patents should be extended in the case of newly developed drugs. However, in other industries new-product development continues despite high development costs, a fact that indicates that the extension is unnecessary.
Which of the following, if true, most strongly supports the pharmaceutical industry’s argument against the challenge made above?
(A) No industries other than the pharmaceutical industry have asked for an extension of the 20-year limit on patent protection.
(B) Clinical trials of new drugs, which occur after the patent is granted and before the new drug can be marketed, often now take as long as 10 years to complete.
(C) There are several industries in which the ratio of research and development costs to revenues is higher than it is in the pharmaceutical industry.
(D) An existing patent for a drug does not legally prevent pharmaceutical companies from bringing to market alternative drugs, provided they are sufficiently dissimilar to the patented drug.
(E) Much recent industrial innovation has occurred in products—for example, in the computer and electronics industries—for which patent protection is often very ineffective.
正确答案B
不是很理解这道题的意思，NN帮忙解释下吧～～～
我顶～
等待解答ing~
答案B指出了医药行业和别的行业不一样的环节。
因为在10年的药品临床试验阶段，药品不能产生效益，但是，20年专利保护期就已经在倒数；
这样，一个新药品能够产生效益的有效时间就被缩小，从而为了弥补这样的损失，需要延长专利保护期。
谢谢
| 欢迎光临 ChaseDream (https://forum.chasedream.com/) | Powered by Discuz! X3.3 |